Enlivex Therapeutics LtdNASDAQ:ENLV
- LAST PRICE1.4200
- TODAY'S CHANGE (%)0.0100 (0.7092%)
- Bid / Lots1.3300/ 10
- Ask / Lots1.4800/ 2
- Open / Previous Close1.4000 / 1.4100
- Day Range
- 52 Week Range
- Volume51,121
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENLV |
|---|---|---|
| 09:32 ET | 3620 | 1.4 |
| 09:36 ET | 432 | 1.4 |
| 09:38 ET | 100 | 1.42 |
| 10:12 ET | 411 | 1.4204 |
| 10:15 ET | 2408 | 1.4202 |
| 10:17 ET | 1100 | 1.42 |
| 10:33 ET | 200 | 1.42 |
| 10:37 ET | 100 | 1.4 |
| 10:39 ET | 100 | 1.405 |
| 11:00 ET | 200 | 1.405 |
| 11:02 ET | 100 | 1.405 |
| 11:08 ET | 500 | 1.4 |
| 11:11 ET | 200 | 1.395 |
| 11:22 ET | 3845 | 1.385 |
| 11:26 ET | 2300 | 1.39 |
| 11:27 ET | 100 | 1.385 |
| 11:31 ET | 1006 | 1.39 |
| 11:51 ET | 3813 | 1.4 |
| 12:16 ET | 100 | 1.4 |
| 12:18 ET | 100 | 1.395 |
| 12:25 ET | 800 | 1.4 |
| 12:27 ET | 2099 | 1.4 |
| 12:30 ET | 100 | 1.4 |
| 12:34 ET | 300 | 1.4 |
| 01:30 ET | 200 | 1.4 |
| 01:35 ET | 300 | 1.4 |
| 01:39 ET | 100 | 1.39 |
| 02:00 ET | 200 | 1.4 |
| 02:06 ET | 400 | 1.4 |
| 02:22 ET | 400 | 1.396 |
| 02:27 ET | 100 | 1.396 |
| 02:31 ET | 800 | 1.41 |
| 02:33 ET | 380 | 1.41 |
| 02:36 ET | 100 | 1.405 |
| 02:38 ET | 300 | 1.41 |
| 02:49 ET | 100 | 1.41 |
| 02:58 ET | 150 | 1.41 |
| 03:05 ET | 3091 | 1.41 |
| 03:07 ET | 396 | 1.44 |
| 03:12 ET | 742 | 1.41 |
| 03:34 ET | 301 | 1.44 |
| 03:52 ET | 2400 | 1.43 |
| 03:56 ET | 1000 | 1.4479 |
| 03:59 ET | 8727 | 1.42 |
Apr 29, 2024
Enlivex CEO Issues Letter to Shareholders -- Perspectives on Recent Events, from 8:00AM ET on Monday Apr 29, 2024 by Dow Jones
8:00AM ET on Monday Apr 29, 2024 by Dow Jones
Apr 23, 2024
DJ Enlivex Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 6:43AM ET on Tuesday Apr 23, 2024 by Dow Jones
6:43AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 22, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enlivex Therapeutics Ltd | 26.5M | -0.9x | --- |
Biora Therapeutics Inc | 26.2M | -0.1x | --- |
NKGen Biotech Inc | 25.2M | -0.5x | --- |
UNITY Biotechnology Inc | 24.8M | -0.6x | --- |
NanoViricides Inc | 24.4M | -2.6x | --- |
Apollomics Inc | 29.7M | -0.1x | --- |
Company Information
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Contact Information
- Headquarters
- 14 Einstein St.NESS-ZIONA, Israel 7403618
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer
- Oren Hershkovitz
- Executive Chairman of the Board
- Shai Novik
- Founder, Chief Scientific Officer and Medical Officer
- Dror Mevorach
- Chief Financial Officer
- Shachar Shlosberger
- Director
- Baruch Halpert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
